Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247128519> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2247128519 endingPage "510" @default.
- W2247128519 startingPage "510" @default.
- W2247128519 abstract "510 Background: The 21 gene Recurrence Score (RS) assay (Oncotype DX) has been validated to quantify the risk of distant recurrence in tamoxifen (tam)-treated pts with N-, ER+ breast cancer. To determine whether the RS assay predicts prognosis, response to tamoxifen, or both, we studied the pts randomized to placebo and tam in NSABP B-14. Methods: Pts were eligible if tumor blocks were available and contained at least 5% invasive cancer. Expression was quantified by the pre-specified 21 gene RT-PCR assay, and the RS was calculated by the pre-specified algorithm. Cox models were used to evaluate the association between potential predictive variables and distant-recurrence free survival (DRFS). Results: There were 645 evaluable pts (355 placebo and 290 tam). A subset of individual genes (Cyclin B1, Survivin, MYBL2, STK15, Ki-67, PR, and GSTM1), the proliferation gene group score and the RS were significantly associated with DRFS in the placebo pts (p<0.05). ER was not associated with DRFS in the placebo pts (p = 0.30), and was not prognostic. In analysis of both arms, the test for interaction of tam treatment and ER was highly significant (p=0.0007), indicating quantitative ER expression predicts tam benefit. The test for interaction of tam treatment and PR was not significant (p=0.64). The absolute and relative tam benefits for each RS risk group are in the Table below. In contrast to quantitative ER expression which is only predictive of tam response, the 21 gene RS assay is both prognostic and predicts the response to tamoxifen. Conclusions: Not all ER + pts benefited equally from tamoxifen. The largest benefits of tamoxifen were observed with high quantitative ER and low RS, while smaller benefits were observed with low quantitative ER and high RS. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Genomic Health Genomic Health Genomic Health" @default.
- W2247128519 created "2016-06-24" @default.
- W2247128519 creator A5004434618 @default.
- W2247128519 creator A5017805619 @default.
- W2247128519 creator A5033033849 @default.
- W2247128519 creator A5046559078 @default.
- W2247128519 creator A5048859997 @default.
- W2247128519 creator A5055013606 @default.
- W2247128519 creator A5056629892 @default.
- W2247128519 creator A5062584735 @default.
- W2247128519 creator A5078045058 @default.
- W2247128519 creator A5078443385 @default.
- W2247128519 date "2005-06-01" @default.
- W2247128519 modified "2023-10-01" @default.
- W2247128519 title "Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer" @default.
- W2247128519 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.510" @default.
- W2247128519 hasPublicationYear "2005" @default.
- W2247128519 type Work @default.
- W2247128519 sameAs 2247128519 @default.
- W2247128519 citedByCount "74" @default.
- W2247128519 countsByYear W22471285192012 @default.
- W2247128519 countsByYear W22471285192013 @default.
- W2247128519 countsByYear W22471285192014 @default.
- W2247128519 countsByYear W22471285192015 @default.
- W2247128519 countsByYear W22471285192016 @default.
- W2247128519 countsByYear W22471285192017 @default.
- W2247128519 countsByYear W22471285192018 @default.
- W2247128519 countsByYear W22471285192019 @default.
- W2247128519 countsByYear W22471285192020 @default.
- W2247128519 countsByYear W22471285192021 @default.
- W2247128519 countsByYear W22471285192022 @default.
- W2247128519 countsByYear W22471285192023 @default.
- W2247128519 crossrefType "journal-article" @default.
- W2247128519 hasAuthorship W2247128519A5004434618 @default.
- W2247128519 hasAuthorship W2247128519A5017805619 @default.
- W2247128519 hasAuthorship W2247128519A5033033849 @default.
- W2247128519 hasAuthorship W2247128519A5046559078 @default.
- W2247128519 hasAuthorship W2247128519A5048859997 @default.
- W2247128519 hasAuthorship W2247128519A5055013606 @default.
- W2247128519 hasAuthorship W2247128519A5056629892 @default.
- W2247128519 hasAuthorship W2247128519A5062584735 @default.
- W2247128519 hasAuthorship W2247128519A5078045058 @default.
- W2247128519 hasAuthorship W2247128519A5078443385 @default.
- W2247128519 hasConcept C121608353 @default.
- W2247128519 hasConcept C126322002 @default.
- W2247128519 hasConcept C142724271 @default.
- W2247128519 hasConcept C143998085 @default.
- W2247128519 hasConcept C204787440 @default.
- W2247128519 hasConcept C27081682 @default.
- W2247128519 hasConcept C2775975398 @default.
- W2247128519 hasConcept C2777176818 @default.
- W2247128519 hasConcept C50382708 @default.
- W2247128519 hasConcept C530470458 @default.
- W2247128519 hasConcept C71924100 @default.
- W2247128519 hasConcept C84606932 @default.
- W2247128519 hasConceptScore W2247128519C121608353 @default.
- W2247128519 hasConceptScore W2247128519C126322002 @default.
- W2247128519 hasConceptScore W2247128519C142724271 @default.
- W2247128519 hasConceptScore W2247128519C143998085 @default.
- W2247128519 hasConceptScore W2247128519C204787440 @default.
- W2247128519 hasConceptScore W2247128519C27081682 @default.
- W2247128519 hasConceptScore W2247128519C2775975398 @default.
- W2247128519 hasConceptScore W2247128519C2777176818 @default.
- W2247128519 hasConceptScore W2247128519C50382708 @default.
- W2247128519 hasConceptScore W2247128519C530470458 @default.
- W2247128519 hasConceptScore W2247128519C71924100 @default.
- W2247128519 hasConceptScore W2247128519C84606932 @default.
- W2247128519 hasIssue "16_suppl" @default.
- W2247128519 hasLocation W22471285191 @default.
- W2247128519 hasOpenAccess W2247128519 @default.
- W2247128519 hasPrimaryLocation W22471285191 @default.
- W2247128519 hasRelatedWork W1771722205 @default.
- W2247128519 hasRelatedWork W2015092588 @default.
- W2247128519 hasRelatedWork W2027175481 @default.
- W2247128519 hasRelatedWork W2103643613 @default.
- W2247128519 hasRelatedWork W2172254302 @default.
- W2247128519 hasRelatedWork W2464051959 @default.
- W2247128519 hasRelatedWork W2478630076 @default.
- W2247128519 hasRelatedWork W2496465202 @default.
- W2247128519 hasRelatedWork W283415470 @default.
- W2247128519 hasRelatedWork W2998725311 @default.
- W2247128519 hasVolume "23" @default.
- W2247128519 isParatext "false" @default.
- W2247128519 isRetracted "false" @default.
- W2247128519 magId "2247128519" @default.
- W2247128519 workType "article" @default.